Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% – Should You Sell?

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) dropped 4.3% during trading on Tuesday . The company traded as low as $11.37 and last traded at $11.4750. Approximately 143,574 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 751,635 shares. The stock had previously closed at $11.99.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on FULC shares. Leerink Partners set a $20.00 price target on Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Wall Street Zen raised shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Bank of America boosted their price objective on Fulcrum Therapeutics from $6.00 to $7.00 and gave the company an “underperform” rating in a report on Tuesday, December 9th. Piper Sandler reaffirmed an “overweight” rating and set a $23.00 target price (up previously from $16.00) on shares of Fulcrum Therapeutics in a report on Monday, December 8th. Finally, Stifel Nicolaus set a $25.00 price target on Fulcrum Therapeutics in a research report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.00.

Fulcrum Therapeutics Stock Performance

The stock has a market cap of $626.71 million, a price-to-earnings ratio of -9.81 and a beta of 3.17. The company’s 50 day simple moving average is $10.44 and its 200 day simple moving average is $8.53.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Sell-side analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Insider Activity

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $13.98, for a total transaction of $58,368,443.22. Following the sale, the insider directly owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert J. Gould sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total value of $165,450.00. Following the sale, the director owned 484,864 shares of the company’s stock, valued at approximately $5,348,049.92. The trade was a 3.00% decrease in their position. The SEC filing for this sale provides additional information. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC boosted its stake in Fulcrum Therapeutics by 865.0% during the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock valued at $989,000 after purchasing an additional 308,854 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Fulcrum Therapeutics during the first quarter valued at $425,000. Exome Asset Management LLC raised its stake in shares of Fulcrum Therapeutics by 143.0% in the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock valued at $1,985,000 after buying an additional 405,538 shares during the period. Strs Ohio purchased a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at $263,000. Finally, Bailard Inc. bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth $185,000. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.